Treatment options for EGFR mutant NSCLC with CNS involvement—Can patients BLOOM with the use of next generation EGFR TKIs?

Lung Cancer

Volumn 108, Issue , 2017, Pages 29-37

  Tan, Chee Seng ^a   Cho, Byoung Chul ^b   Soo, Ross A ^a,c,d  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b Yonsei University College of Medicine   (South Korea)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

AZD3759; BLOOM trial; CNS metastases; Non small cell lung cancer; Osimertinib; Tyrosine kinase inhibitors

Indexed keywords

AFATINIB; AZD 3759; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; OSIMERTINIB; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

BLOOD BRAIN BARRIER; CANCER SURGERY; CANCER THERAPY; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG EFFICACY; HUMAN; LOCAL THERAPY; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REVIEW; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TREATMENT OUTCOME; WHOLE BRAIN RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; GENETICS; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; SECONDARY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 85014489642     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.02.012     Document Type: Review

References (78)

1. [1] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J. Clin. 61 (2011), 69–90.
2. [2] Mujoomdar, A., Austin, J.H.M., Malhotra, R., Powell, C.A., Pearson, G.D.N., Shiau, M.C., et al. Clinical predictors of metastatic disease to the brain from non–small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 242 (2007), 882–888.
3. [3] Ali, A., Goffin, J.R., Arnold, A., Ellis, P.M., Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr. Oncol., 20, 2013, 300.
4. [4] Heon, S., Yeap, B.Y., Britt, G.J., Costa, D.B., Rabin, M.S., Jackman, D.M., et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 16 (2010), 5873–5882, 10.1158/1078-0432.CCR-10-1588.
5. [5] D'Antonio, C., Passaro, A., Gori, B., Del Signore, E., Migliorino, M.R., Ricciardi, S., et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther. Adv. Med. Oncol. 6 (2014), 101–114, 10.1177/1758834014521110.
6. [6] Lagerwaard, F.J., Levendag, P.C., Nowak, P.J., Eijkenboom, W.M., Hanssens, P.E., Schmitz, P.I., Identification of prognostic factors in patients with brain metastases: a reviewof 1292 patients. Int. J. Radiat. Oncol. Biol. Phys. 43 (1999), 795–803 http://www.ncbi.nlm.nih.gov/pubmed/10098435. (Accessed 9 January 2017).
7. [7] Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004), 2129–2139.
8. [8] Mok, T.S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009), 947–957.
9. [9] Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 (2012), 239–246.
10. [10] Sequist, L.V., Yang, J.C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31 (2013), 3327–3334.
11. [11] Rangachari, D., Yamaguchi, N., VanderLaan, P.A., Folch, E., Mahadevan, A., Floyd, S.R., et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88 (2015), 108–111, 10.1016/j.lungcan.2015.01.020.
12. [12] Heon, S., Yeap, B.Y., Lindeman, N.I., Joshi, V.A., Butaney, M., Britt, G.J., et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non–small cell lung cancer with EGFR mutations. Clin. Cancer Res., 18, 2012.
13. [13] Barnholtz-Sloan, J.S., Sloan, A.E., Davis, F.G., Vigneau, F.D., Lai, P., Sawaya, R.E., Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 22 (2004), 2865–2872, 10.1200/JCO.2004.12.149.
14. [14] J.W. Welsh, R. Komaki, A. Amini, M.F. Munsell, W. Unger, P.K. Allen, et al., Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non–small-cell lung cancer, J. Clin. Oncol. 31 (n.d.) 895–902, doi: 10.1200/JCO.2011.40.1174.
15. [15] Grommes, C., Oxnard, G.R., Kris, M.G., Miller, V.A., Pao, W., Holodny, A.I., et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro. Oncol. 13 (2011), 1364–1369, 10.1093/neuonc/nor121.
16. [16] Berger, L.A., Riesenberg, H., Bokemeyer, C., Atanackovic, D., CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer 80 (2013), 242–248, 10.1016/j.lungcan.2013.02.004.
17. [17] Garg, P., Dhakne, R., Belekar, V., Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability. Mol. Divers. 19 (2015), 163–172, 10.1007/s11030-014-9562-2.
18. [18] Deeken, J.F., Löscher, W., The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13 (2007), 1663–1674, 10.1158/1078-0432.CCR-06-2854.
19. [19] Wilhelm, I., Molnár, J., Fazakas, C., Haskó, J., Krizbai, I.A., Role of the blood-brain barrier in the formation of brain metastases. Int. J. Mol. Sci. 14 (2013), 1383–1411, 10.3390/ijms14011383.
20. [20] Togashi, Y., Masago, K., Fukudo, M., Tsuchido, Y., Okuda, C., Kim, Y.H., et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother. Pharmacol. 68 (2011), 1089–1092, 10.1007/s00280-011-1691-z.
21. [21] Jackman, D.M., Holmes, A.J., Lindeman, N., Wen, P.Y., Kesari, S., Borras, A.M., et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J. Clin. Oncol. 24 (2006), 4517–4520, 10.1200/JCO.2006.06.6126.
22. [22] Chen, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Yang, X.-N., Chen, Z.-H., et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 17 (2012), 978–985, 10.1634/theoncologist.2011-0385.
23. [23] Matsumoto, S., Takahashi, K., Iwakawa, R., Matsuno, Y., Nakanishi, Y., Kohno, T., et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int. J. Cancer 119 (2006), 1491–1494, 10.1002/ijc.21940.
24. [24] Luo, D., Ye, X., Hu, Z., Peng, K., Song, Y., Yin, X., et al. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol. 35 (2014), 2437–2444, 10.1007/s13277-013-1323-9.
25. [25] Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer 119 (2013), 4325–4332, 10.1002/cncr.28364.
26. [26] Patchell, R.A., Tibbs, P.A., Walsh, J.W., Dempsey, R.J., Maruyama, Y., Kryscio, R.J., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322 (1990), 494–500, 10.1056/NEJM199002223220802.
27. [27] Alexander, E., Moriarty, T.M., Davis, R.B., Wen, P.Y., Fine, H.A., Black, P.M., et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J. Natl. Cancer Inst. 87 (1995), 34–40 http://www.ncbi.nlm.nih.gov/pubmed/7666461. (Accessed 16 January 2017).
28. [28] Park, H.S., Chiang, V.L., Knisely, J.P., Raldow, A.C., Yu, J.B., Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. Expert Rev. Anticancer Ther. 11 (2011), 1731–1738, 10.1586/era.11.165.
29. [29] Chang, E.L., Wefel, J.S., Hess, K.R., Allen, P.K., Lang, F.F., Kornguth, D.G., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10 (2009), 1037–1044, 10.1016/S1470-2045(09)70263-3.
30. [30] Trifiletti, D.M., Lee, C.-C., Kano, H., Cohen, J., Janopaul-Naylor, J., Alonso-Basanta, M., et al. Stereotactic radiosurgery for brainstem metastases: an international cooperative study to define response and toxicity. Int. J. Radiat. Oncol. Biol. Phys. 96 (2016), 280–288, 10.1016/j.ijrobp.2016.06.009.
31. [31] Nieder, C., Grosu, A.L., Gaspar, L.E., Stereotactic radiosurgery (SRS) for brain metastases: a systematic review. Radiat. Oncol., 9, 2014, 155, 10.1186/1748-717X-9-155.
32. [32] Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 15 (2014), 387–395, 10.1016/S1470-2045(14)70061-0.
33. [33] Kocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B.G., et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 29 (2011), 134–141, 10.1200/JCO.2010.30.1655.
34. [34] Soon, Y.Y., Tham, I.W.K., Lim, K.H., Koh, W.Y., Lu, J.J., Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Lu, J.J., (eds.) Cochrane Database Syst. Rev., 2014, John Wiley & Sons, Ltd, Chichester, UK, D009454, 10.1002/14651858.CD009454.pub2.
35. [35] Tan, C.-S., Gilligan, D., Pacey, S., Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 16 (2015), e447–e459, 10.1016/S1470-2045(15)00246-6.
36. [36] Mulvenna, P., Nankivell, M., Barton, R., Faivre-finn, C., Wilson, P., Mccoll, E., et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiorit. Lancet 6736 (2016), 1–11, 10.1016/S0140-6736(16)30825-X.
37. [37] Grimm, S.A., Treatment of brain metastases: chemotherapy. Curr. Oncol. Rep. 14 (2012), 85–90, 10.1007/s11912-011-0211-y.
38. [38] Schuler, M., Wu, Y.-L., Hirsh, V., O'Byrne, K., Yamamoto, N., Mok, T., et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J. Thorac. Oncol. 11 (2016), 380–390, 10.1016/j.jtho.2015.11.014.
39. [39] Grommes, C., Oxnard, G.R., Kris, M.G., Miller, V.A., Pao, W., Holodny, A.I., et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 13 (2011), 1364–1369, 10.1093/neuonc/nor121.
40. [40] Jackman, D.M., Cioffredi, L.A., Jacobs, L., Sharmeen, F., Morse, L.K., Lucca, J., et al. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget 6 (2015), 4527–4536, 10.18632/oncotarget.2886.
41. [41] Wu, Y.L., Yang, J.-J., Zhou, C., Feng, J., Lu, S., Song, Y., et al. PL03. 05: BRAIN: a phase III trial comparing WBI and chemotherapy with icotinib in NSCLC with brain metastases harboring EGFR mutations (CTONG 1201). J. Thorac. Oncol., 12, 2017, S6, 10.1016/j.jtho.2016.11.007.
42. [42] Lee, S.M., Lewanski, C.R., Counsell, N., Ottensmeier, C., Bates, A., Patel, N., et al. Randomized trial of erlotinib plus whole-Brain radiotherapy for NSCLC patients with multiple brain metastases. JNCI J. Natl. Cancer Inst., 106, 2014, dju151, 10.1093/jnci/dju151.
43. [43] Jiang, T., Min, W., Li, Y., Yue, Z., Wu, C., Zhou, C., Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med. 5 (2016), 1055–1065, 10.1002/cam4.673.
44. [44] Sundar, R., Soong, R., Cho, B.-C., Brahmer, J.R., Soo, R.A., Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 85 (2014), 101–109.
45. [45] Herzberg, B., Campo, M.J., Gainor, J.F., Immune checkpoint inhibitors in non-Small cell lung cancer. Oncologist 22 (2017), 81–88, 10.1634/theoncologist.2016-0189.
46. [46] Shien, K., Papadimitrakopoulou, V.A., Wistuba, I.I., Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer 99 (2016), 79–87, 10.1016/j.lungcan.2016.06.016.
47. [47] Mansfield, A.S., Aubry, M.C., Moser, J.C., Harrington, S.M., Dronca, R.S., Park, S.S., et al. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 27 (2016), 1953–1958, 10.1093/annonc/mdw289.
48. [48] Berghoff, A.S., Inan, C., Ricken, G., Widhalm, G., Dieckmann, K., Birner, P., et al. Tumor-infiltrating lymphocytes (TILS) and PD-L1 expression in non-small cell lung cancer brain metastases (BM) and matched primary tumors (PT). Ann. Oncol. 25 (2014), iv465–iv466, 10.1093/annonc/mdu349.103.
49. [49] Goldberg, S.B., Gettinger, S.N., Mahajan, A., Chiang, A.C., Herbst, R.S., Sznol, M., et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17 (2016), 976–983, 10.1016/S1470-2045(16)30053-5.
50. [50] Lee, C.K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., et al. Checkpoint inhibitors in metastatic EGFR-Mutated non-Small cell lung cancer-A meta-Analysis. J. Thorac. Oncol. 12 (2017), 403–407, 10.1016/j.jtho.2016.10.007.
51. [51] Yi, H.G., Kim, H.J., Kim, Y.J., Han, S.-W., Oh, D.-Y., Lee, S.-H., et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65 (2009), 80–84, 10.1016/j.lungcan.2008.10.016.
52. [52] Lee, S.J., Lee, J.-I., Nam, D.-H., Ahn, Y.C., Han, J.H., Sun, J.-M., et al. Leptomeningeal carcinomatosis in non–Small-Cell lung cancer patients: impact on survival and correlated prognostic factors. J. Thorac. Oncol. 8 (2013), 185–191, 10.1097/JTO.0b013e3182773f21.
53. [53] Park, J.H., Kim, Y.J., Lee, J.-O., Lee, K.-W., Kim, J.H., Bang, S.-M., et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 76 (2012), 387–392, 10.1016/j.lungcan.2011.11.022.
54. [54] Umemura, S., Tsubouchi, K., Yoshioka, H., Hotta, K., Takigawa, N., Fujiwara, K., et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: okayama Lung Cancer Study Group. Lung Cancer 77 (2012), 134–139, 10.1016/j.lungcan.2012.03.002.
55. [55] Riess, J.W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M.A., Ramchandran, K., et al. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin. Lung Cancer 15 (2014), 202–206, 10.1016/j.cllc.2013.12.009.
56. [56] Lee, S.J., Lee, J.-I., Nam, D.-H., Ahn, Y.C., Han, J.H., Sun, J.-M., et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J. Thorac. Oncol. 8 (2013), 185–191.
57. [57] Remon, J., Le Rhun, E., Besse, B., Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era. Cancer Treat. Rev. 53 (2017), 128–137, 10.1016/j.ctrv.2016.12.006.
58. [58] Morris, P.G., Reiner, A.S., Szenberg, O.R., Clarke, J.L., Panageas, K.S., Perez, H.R., et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J. Thorac. Oncol. 7 (2012), 382–385, 10.1097/JTO.0b013e3182398e4f.
59. [59] Gwak, H.-S., Joo, J., Kim, S., Yoo, H., Shin, S.H., Han, J.-Y., et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J. Thorac. Oncol. 8 (2013), 599–605, 10.1097/JTO.0b013e318287c943.
60. [60] Liao, B.-C., Lee, J.-H., Lin, C.-C., Chen, Y.-F., Chang, C.-H., Ho, C.-C., et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non-Small-Cell lung cancer patients with leptomeningeal carcinomatosis. J. Thorac. Oncol. 10 (2015), 1754–1761, 10.1097/JTO.0000000000000669.
61. [61] Ozdemir, Y., Yildirim, B.A., Topkan, E., Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors. J. Neurooncol. 129 (2016), 329–335, 10.1007/s11060-016-2179-9.
62. [62] Tan, C.-S., Cho, B.-C., Soo, R.A., Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer 93 (2016), 59–68, 10.1016/j.lungcan.2016.01.003.
63. [63] Ballard, P., Yates, J.W.T., Yang, Z., Kim, D.-W., Yang, J.C.-H., Cantarini, M., et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin. Cancer Res. 22 (2016), 5130–5140, 10.1158/1078-0432.CCR-16-0399.
64. [64] Yang, J.C.-H., et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study., ASCO Annu. Meet., 2016.
65. [65] Goss, G., et al. CNS response to osimertinib in patients with T790M-Positive advanced NSCLC: pooled data from two phase II trials. World Conf. Lung Cancer, 2016.
66. [66] Yang, Z., Guo, Q., Wang, Y., Chen, K., Zhang, L., Cheng, Z., et al. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci. Transl. Med., 8, 2016, 368ra172, 10.1126/scitranslmed.aag0976.
67. [67] Ahn, M.-J., et al. Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM). ASCO Annu. Meet., 2016.
68. [68] Lin, N.U., Lee, E.Q., Aoyama, H., Barani, I.J., Barboriak, D.P., Baumert, B.G., et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 16 (2015), e270–e278, 10.1016/S1470-2045(15)70057-4.
69. [69] Chamberlain, M., Junck, L., Brandsma, D., Soffietti, R., Rudà, R., Raizer, J., et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol., 2016, now183, 10.1093/neuonc/now183.
70. [70] Clarke, J.L., Pao, W., Wu, N., Miller, V.A., Lassman, A.B., High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J. Neurooncol. 99 (2010), 283–286, 10.1007/s11060-010-0128-6.
71. [71] Masuda, T., Hattori, N., Hamada, A., Iwamoto, H., Ohshimo, S., Kanehara, M., et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother. Pharmacol. 67 (2011), 1465–1469, 10.1007/s00280-011-1555-6.
72. [72] Togashi, Y., Masago, K., Fukudo, M., Tsuchido, Y., Okuda, C., Kim, Y.H., et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother. Pharmacol. 68 (2011), 1089–1092, 10.1007/s00280-011-1691-z.
73. [73] Zhao, J., Chen, M., Zhong, W., Zhang, L., Li, L., Xiao, Y., et al. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin. Lung Cancer 14 (2013), 188–193, 10.1016/j.cllc.2012.06.004.
74. [74] Hoffknecht, P., Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R., Schütz, M., et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J. Thorac. Oncol. 10 (2015), 156–163, 10.1097/JTO.0000000000000380.
75. [75] Wu, Y.-L., Zhou, C., Cheng, Y., Lu, S., Chen, G.-Y., Huang, C., et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann. Oncol. 24 (2013), 993–999, 10.1093/annonc/mds529.
76. [76] Kim, J.-E., Lee, D.H., Choi, Y., Yoon, D.H., Kim, S.-W., Suh, C., et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65 (2009), 351–354, 10.1016/j.lungcan.2008.12.011.
77. [77] Park, S.J., Kim, H.T., Lee, D.H., Kim, K.P., Kim, S.-W., Suh, C., et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77 (2012), 556–560, 10.1016/j.lungcan.2012.05.092.
78. [78] Iuchi, T., Shingyoji, M., Sakaida, T., Hatano, K., Nagano, O., Itakura, M., et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82 (2013), 282–287, 10.1016/j.lungcan.2013.08.016.